Parkside Financial Bank & Trust Buys 31 Shares of Novartis AG (NVS)
Parkside Financial Bank & Trust increased its position in Novartis AG (NYSE:NVS) by 0.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,492 shares of the company’s stock after buying an additional 31 shares during the period. Parkside Financial Bank & Trust’s holdings in Novartis AG were worth $375,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in the company. Howe & Rusling Inc. boosted its position in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares in the last quarter. City Holding Co. boosted its position in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares in the last quarter. TCI Wealth Advisors Inc. boosted its position in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares in the last quarter. Archford Capital Strategies LLC boosted its position in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares in the last quarter. Finally, Kernodle & Katon Asset Management Group LLC boosted its position in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares in the last quarter. 11.16% of the stock is currently owned by institutional investors.
Novartis AG (NYSE:NVS) opened at 83.86 on Tuesday. The stock’s 50 day moving average price is $84.10 and its 200-day moving average price is $78.88. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a market cap of $196.47 billion, a price-to-earnings ratio of 30.62 and a beta of 0.73.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The company’s revenue was down 1.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. Equities analysts expect that Novartis AG will post $4.73 EPS for the current year.
WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/parkside-financial-bank-trust-buys-31-shares-of-novartis-ag-nvs/1488631.html.
A number of brokerages recently commented on NVS. Leerink Swann reaffirmed a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. Morgan Stanley reiterated a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. Zacks Investment Research upgraded Novartis AG from a “strong sell” rating to a “hold” rating in a research note on Monday, May 1st. UBS AG reiterated a “neutral” rating on shares of Novartis AG in a research note on Wednesday, May 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, April 18th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. Novartis AG currently has an average rating of “Hold” and a consensus price target of $83.56.
In related news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.01% of the stock is owned by insiders.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.